Literature DB >> 9669808

Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members.

P Watson1, K M Lin, M A Rodriguez-Bigas, T Smyrk, S Lemon, M Shashidharan, B Franklin, B Karr, A Thorson, H T Lynch.   

Abstract

BACKGROUND: Patients with hereditary nonpolyposis colorectal carcinoma (HNPCC) reportedly have better prognoses than sporadic colorectal carcinoma (CRC) patients, but it has been unclear whether this could be due to differences in stage at diagnosis. The current study compared stage and survival in a retrospective cohort of HNPCC family members who developed CRC with the same factors in an unselected hospital series of patients with sporadic CRC.
METHODS: This retrospective cohort study compared HNPCC cases (274 cases from 98 HNPCC families) with an unselected hospital series comprising 820 consecutive CRC cases. All patients were staged according to the TNM system of the American Joint Committee on Cancer and the International Union Against Cancer. Median follow-up among living patients was > 10 years and 8.5 years, respectively, for the two cohorts. Cox regression was used to compare survival in stage-stratified analyses of time from diagnosis to death.
RESULTS: Compared with the unselected series, the HNPCC cases had lower stage disease (P < 0.001), and fewer had distant metastases at diagnosis (P < 0.001 in an analysis stratified by T classification). In stage-stratified survival analysis, the HNPCC cases had a significant overall survival advantage regardless of adjustment for their younger age. A conservative estimate of the hazard ratio (of HNPCC cases to the unselected series) was 0.67 (P < 0.0012).
CONCLUSIONS: HNPCC patients had lower stage disease at diagnosis than the unselected CRC cases, mainly due to rarer distant metastases at diagnosis. They survived longer than unselected CRC patients with tumors of the same stage. The estimated death rate for the HNPCC cases, adjusted for stage and age differences, was at most two-thirds of the rate for the hospital series.

Entities:  

Mesh:

Year:  1998        PMID: 9669808

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  52 in total

1.  The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program.

Authors:  Aparna Mukherjee; Thomas J McGarrity; Francesca Ruggiero; Walter Koltun; Kevin McKenna; Lisa Poritz; Maria J Baker
Journal:  Hered Cancer Clin Pract       Date:  2010-11-22       Impact factor: 2.857

Review 2.  Microsatellite instability in colorectal cancer.

Authors:  C Richard Boland; Ajay Goel
Journal:  Gastroenterology       Date:  2010-06       Impact factor: 22.682

3.  An alternative to prophylactic colectomy for colon cancer prevention in HNPCC syndrome.

Authors:  H F A Vasen; W H de Vos Tot Nederveen Cappel
Journal:  Gut       Date:  2005-10       Impact factor: 23.059

4.  Not all "mucinous carcinomas" are equal: time to redefine and reinvestigate the biologic significance of mucin types and patterns in the GI tract.

Authors:  N Volkan Adsay; David S Klimstra
Journal:  Virchows Arch       Date:  2005-06-08       Impact factor: 4.064

5.  Detection of germline mutations of hMLH1 and hMSH2 based on cDNA sequencing in China.

Authors:  Chao-Fu Wang; Xiao-Yan Zhou; Tai-Ming Zhang; Meng-Hong Sun; Da-Ren Shi
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

6.  Immunology and the Lynch syndrome.

Authors:  Henry T Lynch; Kristen M Drescher; Albert de la Chapelle
Journal:  Gastroenterology       Date:  2008-04       Impact factor: 22.682

7.  Survival of patients with ovarian cancer due to a mismatch repair defect.

Authors:  Th E M Crijnen; M L G Janssen-Heijnen; H Gelderblom; J Morreau; M A Nooij; G G Kenter; H F A Vasen
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

Review 8.  Hereditary nonpolyposis colorectal cancer (Lynch syndrome): criteria for identification and management.

Authors:  Gregory Kouraklis; Evangelos P Misiakos
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

Review 9.  Clinical significance of microsatellite instability in colorectal cancer.

Authors:  Matthias Kloor; Laura Staffa; Aysel Ahadova; Magnus von Knebel Doeberitz
Journal:  Langenbecks Arch Surg       Date:  2013-09-19       Impact factor: 3.445

10.  Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome.

Authors:  Miriam Reuschenbach; Matthias Kloor; Monika Morak; Nicolas Wentzensen; Anja Germann; Yvette Garbe; Mirjam Tariverdian; Peter Findeisen; Michael Neumaier; Elke Holinski-Feder; Magnus von Knebel Doeberitz
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.